We thought Ozempic was just for weight loss. Science is now seeing it may end alcoholism

A 26-week clinical trial in 108 adults with obesity and alcohol use disorder found semaglutide cut heavy drinking days and total alcohol intake more than placebo.

The study suggests Ozempic’s active ingredient may dampen the brain’s reward response to alcohol, possibly reducing cravings and binge drinking.

Researchers say the findings point to a promising new treatment path for alcoholism using a familiar drug.

However, the results are still early and limited by the small sample size and specific patient group.